文献速递血栓与止血贫血与红细胞疾病

日本先天性血小板减少症注册研究中ANKRD26变异体的差异转录水平与临床表型

Differential transcript level of ANKRD26 and clinical phenotype among the ANKRD26 variants in the Japanese registry for congenital thrombocytopenia.
PubMed 文献 · Br J Haematol · 2025-09-15

该研究在日本先天性血小板减少症注册队列中鉴定了一个新型ANKRD26变异(c.-129_-112del),并分析21例ANKRD26相关血小板减少症患者巨核细胞的ANKRD26转录水平。新型变异转录水平显著高于既往报道变异(p<0.001),但无特征性临床表型,巨核细胞前血小板形成减少、核倍性降低,RNA测序显示细胞增殖相关基因上调,提示可能与白细胞增多相关但需进一步研究确认。

要点

  • 新型ANKRD26变异c.-129_-112del转录水平显著高于既往报道变异(p<0.001),但无特征性临床表型。
  • 该变异巨核细胞前血小板形成减少、核倍性降低,并上调DOCK2、CD38和IL1RAP等增殖相关基因。
  • 结果提示该变异可能与白细胞增多相关,但需进一步研究确认。

核心结论

  • 新型ANKRD26变异破坏RUNX1结合位点导致ANKRD26过表达和可能的造血异常,但未与临床严重程度直接相关。
  • 细胞增殖相关基因(CD38、DOCK2和IL1RAP)表达增加,结果提示可能与白细胞增多相关,但需进一步研究确认。

研究设计与样本

  • 研究纳入日本先天性血小板减少症注册队列中的21例ANKRD26相关血小板减少症患者。
  • 采用定量逆转录微滴数字聚合酶链反应(PCR)分析巨核细胞中ANKRD26转录水平,并评估血小板功能、巨核细胞形态和RNA测序。

主要发现

  • 新型变异c.-129_-112del的ANKRD26转录水平显著高于既往报道变异(p<0.001),但无特征性临床表型。
  • 携带新型变异的巨核细胞前血小板形成减少、核倍性降低。
  • RNA测序显示细胞增殖基因DOCK2、CD38和IL1RAP上调,除ANKRD26外未检测到其他血小板或巨核细胞相关基因变异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ankyrin repeat domain 26 (ANKRD26)-related thrombocytopenia (ANKRD26-RT) is an autosomal dominant disorder caused by variants in the 5'-untranslated region of the ANKRD26 gene, leading to its overexpression and impaired megakaryocyte maturation. We identified a novel ANKRD26 variant (c.-129_-112del) and investigated its transcriptional impact, platelet function, and haematopoietic effects. We analysed ANKRD26 transcription in megakaryocytes derived from 21 ANKRD26-RT patients using quantitative reverse transcription droplet digital polymerase chain reaction (PCR). Furthermore, platelet function, megakaryocyte morphology and RNA sequencing were assessed. The novel variant exhibited significantly higher ANKRD26 transcription levels than previously reported variants (p < 0.001), but did not show any characteristic clinical phenotypes. Megakaryocytes with the novel variant showed reduced proplatelet formation and lower nuclear ploidy. RNA sequencing revealed upregulation of cell proliferation genes, including dedicator of cytokinesis 2 (DOCK2), cluster of differentiation (CD38) and interleukin-1 receptor accessory protein (IL1RAP). No platelet-related or megakaryocyte-related genes other than ANKRD26 were detected in these variants. The new variant disrupted the runt-related transcription factor 1 (RUNX1)-binding site, leading to ANKRD26 overexpression and possible haematopoietic abnormalities, though it did not directly correlate with clinical severity. However, genes linked to cell proliferation (CD38, DOCK2 and IL1RAP) showed increased expression. Our results suggested a potential link to leucocytosis, although further research is required to confirm this.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Sakamoto A, Uchiyama T, Nakabayashi K, et al. Differential transcript level of ANKRD26 and clinical phenotype among the ANKRD26 variants in the Japanese registry for congenital thrombocytopenia. Br J Haematol. 2025. PMID: 40954090. doi:10.1111/bjh.70169

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。